Clinical Trial Update: Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line capecitabine with or without sunitinib malate in metastatic esophageal or gastroesophageal junction adenocarcinoma; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-07-24